Connors Investor Services Inc. Has $2.46 Million Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Connors Investor Services Inc. cut its stake in Cryoport, Inc. (NASDAQ:CYRX) by 20.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,076 shares of the company’s stock after selling 35,938 shares during the period. Connors Investor Services Inc. owned approximately 0.28% of Cryoport worth $2,462,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CYRX. Vanguard Group Inc. increased its stake in shares of Cryoport by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 3,559,092 shares of the company’s stock valued at $48,795,000 after purchasing an additional 74,037 shares during the last quarter. Cadian Capital Management LP increased its stake in shares of Cryoport by 30.4% in the 4th quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock valued at $53,659,000 after purchasing an additional 807,340 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Cryoport by 46.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after purchasing an additional 636,395 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Cryoport by 29.9% in the 4th quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock valued at $25,446,000 after purchasing an additional 378,340 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Cryoport by 487.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,393,156 shares of the company’s stock valued at $21,580,000 after purchasing an additional 1,156,106 shares during the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Richard J. Berman sold 8,105 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total value of $108,688.05. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $1,341,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Richard J. Berman sold 8,105 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total value of $108,688.05. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $1,341,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Edward J. Zecchini sold 3,443 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $13.37, for a total value of $46,032.91. Following the completion of the transaction, the insider now directly owns 60,051 shares in the company, valued at $802,881.87. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.

Cryoport Price Performance

CYRX stock traded up $0.16 during midday trading on Friday, reaching $8.67. 851,710 shares of the stock were exchanged, compared to its average volume of 1,163,204. The stock has a market capitalization of $427.08 million, a PE ratio of -3.51 and a beta of 1.59. Cryoport, Inc. has a 52 week low of $5.32 and a 52 week high of $20.10. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22. The company has a fifty day moving average price of $9.45 and a 200 day moving average price of $13.79.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. The company had revenue of $54.59 million during the quarter, compared to the consensus estimate of $58.78 million. During the same quarter last year, the firm posted ($0.16) EPS. The company’s quarterly revenue was down 13.1% on a year-over-year basis. As a group, analysts expect that Cryoport, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. B. Riley lowered Cryoport from a “buy” rating to a “neutral” rating and decreased their price target for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Jefferies Financial Group started coverage on Cryoport in a research note on Thursday, April 4th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Cryoport in a research report on Wednesday, May 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $19.43.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.